Our INSTI® platform adapted to HIV resulted in a highly accurate HIV antibody test that provides a result in 60 seconds or less, far faster than the 15-20 minutes required for tests based on lateral flow technology. The speed of INSTI® generates meaningful clinical and financial advantages that translate into a compelling value proposition for patients, healthcare professionals, payers and public health organizations.
The INSTI® platform is highly adaptable to a wide range of infectious and other diseases. bioLytical® Laboratories is committed to expanding its product lines by deploying the INSTI® platform to disease states where significant unmet public health needs intersect with commercial opportunity. Our R&D team is focused on advancing our product pipeline and also provides contract development services for novel applications of the INSTI® platform.